Insider Selling: Vir Biotechnology (NASDAQ:VIR) Major Shareholder Sells 227,803 Shares of Stock

Vir Biotechnology, Inc. (NASDAQ:VIR) major shareholder Endurance (Cayman) Ltd Svf sold 227,803 shares of Vir Biotechnology stock in a transaction on Monday, November 24th. The shares were sold at an average price of $6.15, for a total value of $1,400,988.45. Following the sale, the insider directly owned 14,346,180 shares of the company’s stock, valued at approximately $88,229,007. The trade was a 1.56% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Major shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Endurance (Cayman) Ltd Svf also recently made the following trade(s):

• On Tuesday, November 25th, Endurance (Cayman) Ltd Svf sold 235,971 shares of Vir Biotechnology stock. The shares were sold at an average price of $6.38, for a total value of $1,505,494.98.
• On Wednesday, October 29th, Endurance (Cayman) Ltd Svf sold 100 shares of Vir Biotechnology stock. The shares were sold at an average price of $6.49, for a total transaction of $649.00.
• On Tuesday, October 28th, Endurance (Cayman) Ltd Svf sold 24,453 shares of Vir Biotechnology stock. The stock was sold at an average price of $6.50, for a total transaction of $158,944.50.
• On Monday, October 27th, Endurance (Cayman) Ltd Svf sold 66,403 shares of Vir Biotechnology stock. The shares were sold at an average price of $6.05, for a total transaction of $401,738.15.
• On Friday, October 24th, Endurance (Cayman) Ltd Svf sold 46,696 shares of Vir Biotechnology stock. The shares were sold at an average price of $5.96, for a total transaction of $278,308.16.
• On Thursday, October 23rd, Endurance (Cayman) Ltd Svf sold 154,383 shares of Vir Biotechnology stock. The stock was sold at an average price of $5.99, for a total value of $924,754.17.
• On Wednesday, October 22nd, Endurance (Cayman) Ltd Svf sold 144,266 shares of Vir Biotechnology stock. The stock was sold at an average price of $6.15, for a total value of $887,235.90.
• On Tuesday, October 21st, Endurance (Cayman) Ltd Svf sold 109,675 shares of Vir Biotechnology stock. The shares were sold at an average price of $6.30, for a total value of $690,952.50.
• On Monday, October 20th, Endurance (Cayman) Ltd Svf sold 220,535 shares of Vir Biotechnology stock. The shares were sold at an average price of $6.20, for a total transaction of $1,367,317.00.
• On Thursday, October 16th, Endurance (Cayman) Ltd Svf sold 12,844 shares of Vir Biotechnology stock. The stock was sold at an average price of $6.10, for a total transaction of $78,348.40.

Vir Biotechnology Trading Down 0.8%

VIR traded down $0.05 during trading on Wednesday, hitting $6.39. The stock had a trading volume of 1,892,329 shares, compared to its average volume of 1,543,817. The company has a 50 day simple moving average of $5.68 and a 200-day simple moving average of $5.27. The firm has a market cap of $888.98 million, a PE ratio of -1.77 and a beta of 1.27. Vir Biotechnology, Inc. has a 12 month low of $4.16 and a 12 month high of $14.45.

Vir Biotechnology (NASDAQ:VIR) last announced its quarterly earnings data on Wednesday, November 5th. The company reported ($1.17) earnings per share for the quarter, missing the consensus estimate of ($0.70) by ($0.47). The firm had revenue of $0.24 million for the quarter, compared to analyst estimates of $1.98 million. Vir Biotechnology had a negative return on equity of 50.76% and a negative net margin of 2,963.54%.Vir Biotechnology’s revenue for the quarter was up .8% compared to the same quarter last year. During the same period in the previous year, the business posted ($1.56) EPS. As a group, sell-side analysts anticipate that Vir Biotechnology, Inc. will post -3.92 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Vir Biotechnology

A number of hedge funds and other institutional investors have recently modified their holdings of VIR. Raymond James Financial Inc. acquired a new stake in shares of Vir Biotechnology in the second quarter valued at approximately $35,000. Federated Hermes Inc. raised its position in Vir Biotechnology by 153.8% during the third quarter. Federated Hermes Inc. now owns 8,085 shares of the company’s stock valued at $46,000 after purchasing an additional 4,899 shares in the last quarter. Apollon Wealth Management LLC acquired a new position in Vir Biotechnology during the second quarter valued at approximately $50,000. Daiwa Securities Group Inc. lifted its stake in Vir Biotechnology by 2,200.6% during the second quarter. Daiwa Securities Group Inc. now owns 12,308 shares of the company’s stock worth $62,000 after purchasing an additional 11,773 shares during the last quarter. Finally, Los Angeles Capital Management LLC acquired a new stake in shares of Vir Biotechnology in the 2nd quarter valued at $63,000. Institutional investors and hedge funds own 65.32% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on VIR. Weiss Ratings reissued a “sell (e+)” rating on shares of Vir Biotechnology in a research note on Monday. Bank of America upgraded Vir Biotechnology from a “neutral” rating to a “buy” rating and raised their target price for the stock from $12.00 to $14.00 in a report on Wednesday, August 27th. Evercore ISI began coverage on Vir Biotechnology in a research report on Wednesday, September 3rd. They set an “outperform” rating and a $12.00 target price for the company. Finally, HC Wainwright reiterated a “buy” rating and issued a $15.00 price target on shares of Vir Biotechnology in a research report on Monday, September 15th. Nine equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $17.30.

About Vir Biotechnology

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).